Renal Cell Carcinoma

The combination of durvalumab and tremelimumab improved disease-free survival compared with active monitoring but efficacy came with increased toxicity.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

The LITESPARK-024 trial showed a manageable safety profile for belzutifan and palbociclib in advanced RCC, but the response rate did not exceed that of historical single-agent belzutifan.

Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.

NPX372 received Investigational New Drug Clearance from the FDA, allowing for clinical development.

During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal cell carcinoma, highlighting management of anemia and hypoxia.

Experts discuss second-line treatment strategies for clear cell renal cell carcinoma, focusing on efficacy, tolerability, and the role of tivozanib.

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed their approaches to TKI dose modification and immune checkpoint inhibitor rechallenge in advanced renal cell carcinoma.

During a live event, Kathryn E. Beckermann, MD, PhD, and participants discussed whether risk stratification factors into the choice of a combination regimen for advanced renal cell carcinoma.

XmAb819 shows promising antitumor activity and manageable safety in clear cell renal cell carcinoma patients, highlighting its potential in future therapies.

Immunotherapy shows significant survival benefits for metastatic chromophobe renal cell carcinoma patients with sarcomatoid features, suggesting a potential predictive biomarker.

During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma and evaluated the findings on dual immunotherapy in this setting.

A study reveals cabozantinib plus nivolumab shows a 71% response rate in fumarate hydratase-deficient renal cell carcinoma, promising survival outcomes.

High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens for non–clear cell renal cell carcinoma.

A phase 1b/2 trial shows triplet therapy for advanced renal cell carcinoma is feasible but lacks significant response improvement over standard treatment.

The FDA grants fast track designation to a new noninvasive diagnostic agent for clear cell renal cell carcinoma, promising improved patient outcomes.

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.

Belzutifan shows promising disease control and manageable safety in advanced VHL disease, with notable tumor responses and anemia as a common adverse effect.

A study reveals that lower KIM-1 levels predict better outcomes in advanced renal cell carcinoma patients treated with nivolumab and ipilimumab.

New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.

XmAb819 shows promising antitumor activity and safety in advanced clear cell renal cell carcinoma, paving the way for future clinical advancements.

During a live event, Che-Kai Tsao, MD, MS, and participants gave their reasoning for their choice of combination therapy for a 65-year-old patient with high-burden metastatic renal cell carcinoma.